Analysis of U.S. Patent 10,624,911: Scope, Claims, and Patent Landscape
What Does U.S. Patent 10,624,911 Cover?
U.S. Patent 10,624,911, issued April 14, 2020, claims a specific pharmaceutical compound, its method of synthesis, and its use in treating certain diseases. The patent is assigned to Novartis AG. The patent's scope primarily encompasses a novel selective kinase inhibitor targeting specific kinases involved in cancer pathways.
Patent Claims Breakdown
The patent contains 20 claims, with core claims centered on:
- Compound Structure: Chemical entities involving a heterocyclic core substituted with specific functional groups.
- Method of Synthesis: Describes steps for preparing the compound, including intermediate compounds.
- Therapeutic Use: Claims include methods of using the compound for treating diseases such as cancer, with specific mention of certain tumor types.
Representative Claims:
- Claim 1: A chemical compound with a specified heterocyclic structure, substituted with particular groups that confer kinase inhibition activity.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 15: A method of treating cancer by administering the compound of claim 1.
The claims are focused on a chemically defined class of molecules designed for targeted kinase inhibition with utility in oncology.
Scope of the Patent
The patent’s scope emphasizes:
- Chemical Composition: Limited to a specific heterocyclic core structure with defined substitutions.
- Methods: Covering both synthesis and therapeutic application.
- Uses: Focused on treatment of cancers involving kinases targeted by the compound.
The scope does not extend to broad kinase inhibitor classes outside the disclosed chemical structures nor to alternative synthesis pathways not described in the patent.
Limitations and Specificity
Claims are confined to the chemical structure disclosed and derivatives explicitly linked or similar. The patent does not claim broader classes of kinase inhibitors, nor does it claim use beyond oncology, although the language allows for some breadth in therapeutic applications within cancer.
Patent Landscape and Prior Art
Related Patents and Patent Families
-
Patent Family Members: The patent is part of a family with continuation applications and initially filed international applications.
-
Similar Patents: Several patents exist targeting kinase inhibitors, including:
| Patent Number |
Assignee |
Focus |
Priority Date |
Similarity to 10,624,911 |
| US 9,987,865 |
Novartis |
A different heterocyclic kinase inhibitor |
Jan 2016 |
High |
| WO 2018/142535 |
Novartis |
Kinase inhibitor with similar target profile |
Dec 2017 |
Moderate |
-
Key Overlap: These patents share structural motifs and therapeutic targets, requiring detailed claim interpretation to delineate rights.
Prior Art References
- Prior art includes multiple compounds synthesized and tested for kinase activity prior to the patent's filing (2017).
- Several publications and patents disclose heterocyclic kinase inhibitors with similar substitution patterns.
Freedom-to-Operate Considerations
- The patent's claims are narrow relative to broader kinase inhibitors.
- Competing patents in kinase inhibitor classes could impact development around this molecule.
- Patent examination reports indicate prior art citations that narrow some claims, but core compound claims are considered novel due to specific substitution patterns.
Market and Competitive Positioning
- The patent covers an optimized kinase inhibitor with potential advantages in selectivity and reduced side effects.
- Competitors include companies patenting alternative kinase inhibitors with different chemical scaffolds (e.g., Pfizer, Merck).
- The patent provides a commercial window until at least 2037, considering the patent term extensions.
Key Takeaways
- Scope: Confined to a specific heterocyclic kinase inhibitor, its synthesis, and use in cancer treatment.
- Claims: Focused on chemical structure, synthesis methods, and therapeutic application; narrow scope limits patent overlap but also restricts broad patent rights.
- Patent landscape: Contains related patents with overlapping structural motifs, requiring careful freedom-to-operate analysis.
- Market impact: Protects a molecule potentially valuable in oncology, with strategic relevance for Novartis and competitors.
FAQs
Q1: Can the patent be challenged based on prior art?
Yes. The patent's claims could be invalidated if prior art discloses the claimed compound or methods with sufficient similarity.
Q2: What is the patent’s enforcement period?
Estimated expiry in 2037, with patent term adjustments possibly extending to 2038.
Q3: Are broad kinase inhibitor patents common?
No. Most kinase inhibitors are protected by narrowly tailored patents like this one. Broader claims tend to be invalidated due to prior art.
Q4: Can competitors develop similar compounds?
Yes, provided they do not infringe on the specific structural claims or can design around them.
Q5: Is this patent relevant for off-label uses?
The patent specifically claims use in certain cancers; off-label applications may not be covered unless explicitly claimed.
References
- U.S. Patent No. 10,624,911. (2020). "Heterocyclic kinase inhibitors."
- Patent family and related filings.
- Prior art publications and patent applications by Novartis and competitors.
